{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/maximizing-output-phase-i-streamline-clinical-development-0#webpage",
"url": "https://www.fortrea.com/insights/maximizing-output-phase-i-streamline-clinical-development-0",
"name": "Maximizing the output of Phase I to streamline clinical development",
"description": "This Fortrea case study explores how Phase I clinical development optimization was applied to support an inhaled drug development program using an alternative delivery platform for an approved therapy. The study focused on defining dose strategy, evaluating pharmacokinetic characteristics, and incorporating FDA feedback to support streamlined clinical progression and regulatory planning. The case study highlights operational and scientific challenges related to dose definition, balancing peak drug concentration and therapeutic effect, and aligning development activities with regulatory expectations during early-phase clinical development. Fortrea supported the sponsor through clinical development strategy consulting, regulatory coordination, and execution planning designed to reduce delays and improve decision-making across the program. By integrating early-phase clinical trial consulting with structured dose optimization and regulatory strategy support, the approach enabled more efficient clinical development planning and progression toward U.S. registration objectives. Fortrea Case Study."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maximizing the output of Phase I to streamline clinical development",
"item": "https://www.fortrea.com/insights/maximizing-output-phase-i-streamline-clinical-development-0"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/maximizing-output-phase-i-streamline-clinical-development-0#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/maximizing-output-phase-i-streamline-clinical-development-0#webpage"
},
"headline": "Phase I Clinical Development Optimization and Dose Strategy Planning | Fortrea Case Study",
"description": "This Fortrea case study explores how Phase I clinical development optimization was applied to support an inhaled drug development program using an alternative delivery platform for an approved therapy. The study focused on defining dose strategy, evaluating pharmacokinetic characteristics, and incorporating FDA feedback to support streamlined clinical progression and regulatory planning. The case study highlights operational and scientific challenges related to dose definition, balancing peak drug concentration and therapeutic effect, and aligning development activities with regulatory expectations during early-phase clinical development. Fortrea supported the sponsor through clinical development strategy consulting, regulatory coordination, and execution planning designed to reduce delays and improve decision-making across the program. By integrating early-phase clinical trial consulting with structured dose optimization and regulatory strategy support, the approach enabled more efficient clinical development planning and progression toward U.S. registration objectives. Fortrea Case Study.",
"genre": "Case Study",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-11-26",
"dateModified": "2025-11-26",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-11/phase1-streamlining-clinical-development.pdf",
"encodingFormat": "application/pdf"
}
}
]
}